Lappe's Second Check in Weeks Lands at the Yearly Floor

ISB Research · Favorable · sent to Ultimate members October 14, 2026

Mark Lappe runs Inhibrx, a clinical-stage biotech building biologic drugs for cancers like chondrosarcoma, and he just put another $840,401 into his own stock. This is his second buy in a month, pushing his 30-day total past $1.8 million, and he's written 14 checks here in the past year. What makes this one worth your time: the stock is sitting at the bottom of its yearly range with RSI under 30, while the broad market is still holding above its short-term trend. That combination has the best record of any setup we track, and healthcare is one of the few corners catching a defensive bid right now. One honest note before you get excited. Past insider buys on this name have been a coin flip at 30 days and slightly negative at 90, so the CEO's conviction is carrying this, not the historical bounce.

Ultimate members received this analysis in real time.